Intervacc is trading 9.5% down at €0.08 after the August 6, 2026 session, with no fresh company-specific negative announcement found to explain the decline.
- Recent coverage concerns the July 30 EMA application to extend Strangvac’s immunity claim to 12 months and New Zealand’s special-permit import approval, both positive developments.
- Biotech sector strength does not align with Intervacc’s decline.
- Trading activity and volume information were unavailable; the market is closed.